- Conditions
- Acquired Brain Injury, Mild Cognitive Impairment, Mild Neurocognitive Disorder
- Interventions
- Cognitive Computerized Training
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1177–1200
of 2,407
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension
- Interventions
- telmisartan, valsartan
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 16
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 12 more
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Guided, Self-directed
- Behavioral
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bloomington, Minnesota
- Conditions
- Renal Impairment
- Interventions
- SAR302503
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
- Conditions
- Mild Cognitive Impairment, Amnestic Mild Cognitive Impairment - aMCI
- Interventions
- NeuroElectric StarStim, Sham Treatment
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Traumatic Brain Injury
- Interventions
- Citicoline, Placebo
- Drug
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years to 35 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
- Interventions
- Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
- Other · Diagnostic Test · Genetic
- Lead sponsor
- University of Rhode Island
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 4
- States / cities
- Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more
- Conditions
- Traumatic Brain Injury, Post Traumatic Stress Disorder, Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 289 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2021
- U.S. locations
- 19
- States / cities
- Sun City, Arizona • Irvine, California • La Jolla, California + 14 more
- Conditions
- Mild Cognitive Impairment, Healthy Aging
- Interventions
- The Computerized Functional Skills Assessment and Training Program, Brain HQ Double Decision
- Device
- Lead sponsor
- i-Function, Inc.
- Industry
- Eligibility
- 60 Years to 100 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Miami, Florida • New York, New York
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia, Cognitive Decline, Dementia, Alzheimer Type
- Interventions
- Renew NCP-5
- Device
- Lead sponsor
- Renew Research, LLC
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Irvine, California • Lady Lake, Florida + 7 more
- Conditions
- Dementia, Mild, Mild Cognitive Impairment (MCI)
- Interventions
- Let's Talk Tech
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cognitive Dysfunction
- Interventions
- Whole-practice cognitive optimization
- Other
- Lead sponsor
- National University of Natural Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Encinitas, California
- Conditions
- Hepatic Insufficiency
- Interventions
- Alisporivir
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Concussion
- Interventions
- NNZ-2566, Placebo
- Drug
- Lead sponsor
- Neuren Pharmaceuticals Limited
- Industry
- Eligibility
- 16 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Fayetteville, North Carolina
- Conditions
- Alzheimer Disease
- Interventions
- LY3002813, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 3 more
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- Nicotinamide, Placebo Comparator
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Irvine, California • Los Angeles, California
- Conditions
- Mild Traumatic Brain Injury
- Interventions
- Diagnostic test
- Device
- Lead sponsor
- Carey Balaban
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- San Diego, California • Miami, Florida • Pittsburgh, Pennsylvania
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
- Interventions
- Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
- Drug · Dietary Supplement
- Lead sponsor
- Michal Schnaider Beeri, Ph.D.
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Mild Cognitive Impairment
- Interventions
- computerized cognitive exercises
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
- Interventions
- Somatropin, Placebo
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 13 more
- Conditions
- Diabetes, Gestational
- Interventions
- nutritional counseling, self blood glucose monitoring
- Behavioral
- Lead sponsor
- The George Washington University Biostatistics Center
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 7,381 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2013
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 13 more
- Conditions
- Alzheimer's Disease
- Interventions
- Computer-based Cognitive Training
- Procedure
- Lead sponsor
- Posit Science Corporation
- Industry
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hepatic Impairment
- Interventions
- Lemborexant
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Aplastic Anemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Fanconi Anemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Paroxysmal Nocturnal Hemoglobinuria, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia
- Interventions
- fludarabine phosphate, melphalan, total-body irradiation, allogeneic hematopoietic stem cell transplantation, anti-thymocyte globulin
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 3 Years to 75 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Buffalo, New York